Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer ( CRPC ) Patients: CaPA Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71149 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Pedro Costa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Vila Nova de Gaia Hospital Center, Vila Nova de Gaia, Portugal. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen-Cilag Farmaceutica Lda.
Abstract (Originalsprache)
Background
Prostate cancer (PC) patients resistant to castration have decreased survival. Analysis of patient characteristics and disease management can contribute to new strategies to prevent or delay progression to castrate‐resistant prostate cancer (CRPC). This study aimed to characterize and compare PC patients from initial PC diagnosis to metastatic CRPC (mCRPC) versus nonmetastatic (nmCRPC) stages in a real‐world setting in Portugal.
Methods
A multicenter, retrospective, non‐interventional study was conducted across 18 Portuguese sites. Consenting adult patients (age ≥ 18 years) diagnosed with CRPC, either metastatic or nonmetastatic, were included in the study at the time of diagnosis or within 12 months of CRPC diagnosis.
Results
Between November 2020 and December 2022, a total of 121 patients (73 mCRPC patients and 48 nmCRPC patients) were included. At diagnosis, the median age was 69.0 and 70.0 years in mCRPC and nmCRPC patients, respectively, and the most common histological subtype was acinar adenocarcinoma (mCRPC: 83.6%; nmCRPC: 91.7%). Significant differences were observed between the two groups regarding Eastern Cooperative Oncology Group Performance status (ECOG PS) ( p = 0.023), Gleason score ( p = 0.001), and American Joint Committee on Cancer (AJCC) stage ( p < 0.001). The median time from PC diagnosis to first treatment and the treatments used prior to CRPC diagnosis were comparable between the groups. However, the median time from PC diagnosis to CRPC was significantly shorter in mCRPC versus nmCRPC patients (42.0 vs. 58.0 months, p = 0.006). Prostate‐specific antigen (PSA) values were significantly higher in mCRPC than in nmCRPC patients at CRPC diagnosis (19.8 vs. 6.3 ng/mL; p < 0.001).
Conclusions
This real‐world study showed that the time from initial PC diagnosis to castration resistance was significantly longer in nmCRPC than in mCRPC patients. The characteristics associated with a better prognosis at initial diagnosis and a better treatment response in nmCRPC patients might explain this difference in disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Department, Vila Nova de Gaia Hospital Center, Vila Nova de Gaia, Portugal.
- Urology Department, Baixo Vouga Hospital Center, Aveiro, Portugal.
- Oncology Department, SAMS Lisbon, Lisbon, Portugal.
- Urology Department, Western Lisbon Hospital Center, Lisbon, Portugal.
- Urology Department, University Hospital Center of Central Lisbon, Lisbon, Portugal.
- Urology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
ORCID-Profile: José Palma Dos Reis
Förderung
- Janssen-Cilag Farmaceutica Lda
Zitieren
APA
Costa, P., Patrício, A., Barreira, J. V., Abranches Monteiro, L., Campos Pinheiro, L., Azinhais, P., Sequeira, I., Rabaça, C., Pereira, F., Borges, R., Botelho, F., Reis, F., Carvalho, J., Canelas, A., Coelho, H., Vila, F., Dinis, R., Dias, S., Fialho, A. C., & Palma Dos Reis, J. (2025). Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer ( CRPC ) Patients: CaPA Study. Cancer Medicine. https://doi.org/10.1002/cam4.71149
Vancouver
Costa P, Patrício A, Barreira JV, Abranches Monteiro L, Campos Pinheiro L, Azinhais P, et al. Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer ( CRPC ) Patients: CaPA Study. Cancer Medicine. 2025. doi:10.1002/cam4.71149
BibTeX
@article{Costa2025,
author = {Costa, Pedro and Patrício, António and Barreira, João Vasco and Abranches Monteiro, Luís and Campos Pinheiro, Luís and Azinhais, Paulo and Sequeira, Inês and Rabaça, Carlos and Pereira, Ferdinando and Borges, Ricardo and Botelho, Francisco and Reis, Frederico and Carvalho, José and Canelas, António and Coelho, Hugo and Vila, Fernando and Dinis, Rui and Dias, Sílvia and Fialho, Ana Cristina and Palma Dos Reis, José},
title = {Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate‐Resistant Prostate Cancer ( CRPC ) Patients: CaPA Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71149}
}
EUVIMED